Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Experimental gene therapy hopes to quiet seizures in kids with rare STXBP1 brain disease

NCT ID NCT06983158

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 31 times

Summary

This early-stage trial tests a single dose of CAP-002 gene therapy in 12 children aged 18 months to 8 years with STXBP1 encephalopathy, a genetic condition that causes severe seizures and developmental delays. The main goal is to check safety, but researchers will also track whether the therapy reduces seizures and improves development over 2 years. The study is currently suspended.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Buerger Center for Advanced Pediatric Care, Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19146, United States

  • Colorado Child Health Research Institute

    Aurora, Colorado, 80045, United States

  • Texas Children's Hospital

    Houston, Texas, 77030, United States

  • Weill Cornell Medicine

    New York, New York, 10021, United States

Conditions

Explore the condition pages connected to this study.